PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a standalone ...
An estimated 21 million American adults suffer from clinical depression. Major depressive disorder affects an estimated 8.3% of the adult population. And now there’s a new option for treatment: ...
Intranasal ketamine delivers a rapid antidepressant effect in patients with treatment-resistant major depressive disorder (MDD), new research shows. Investigators report that the N-methyl-D-asparate ...
A slow-release, twice-a-week ketamine tablet significantly reduced depression symptoms, according to the results of a clinical trial. The tablet can be taken at home without medical supervision, ...
Hosted on MSN
Two forms of ketamine therapy can reduce symptom severity in patients with treatment-resistant depression
A new study led by Mass General Brigham investigators compared the effects of repeated intravenous (IV) ketamine and intranasal (IN) esketamine in patients with treatment-resistant depression. In a ...
UNDATED (CNN/CNN Newsource/WKRC) - The FDA just approved a ketamine-derived nasal spray for helping to treat depression. The Food and Drug Administration (FDA) has approved Spravato, a nasal spray ...
Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk’s reported microdosing, to its portrayal in Hulu’s “The Secret Lives of Mormon Wives.” Ketamine, ...
Johnson & Johnson medication Spravato, a ketamine-based nasal spray, was approved Tuesday by the Food and Drug Administration for use as a sole treatment for depression. Spravato was first approved by ...
15hon MSN
The rise of ketamine and its risks as Matthew Perry’s doctor faces sentencing in his overdose death
Perry, 54, was found by his live-in assistant floating face down and lifeless in the hot tub of his Los Angeles home in ...
An extended-release oral tablet formulation of ketamine has shown promise for treatment-resistant depression (TRD) results of a phase 2 proof-of-concept study suggest. In the trial, twice weekly ...
"Use of an extended-release oral dosage ketamine formulation may be advantageous compared with intranasal or intravenous dosing." HealthDay News — For patients with treatment-resistant depression, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback